Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. (KDNY) Stock Overview
Explore Chinook Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.7B
P/E Ratio
-14.08
EPS (TTM)
$-3.24
ROE
-0.41%
KDNY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Chinook Therapeutics, Inc. (KDNY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $72.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -14.08 and a market capitalization of 2.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.